Consensus Repligen Corporation

Stocks

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 08/07/2026 BST			5-day change	1st Jan Change
137.41 ^USD	-1.73%		+0.71%	-16.14%

07-07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
06-29	Repligen Corporation(NasdaqGS:RGEN) dropped from Russell Small Cap Comp Growth Benchmark	CI

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

ac607867fab3e40.LgvIYoqdx70d1sSOnD--8Cg57_pKMAdHN-bmMsqc6gg.X3KnDuzUqPhe477J2Q3Eu0dV3qMBalIVdtarWKbw0k4Zb_oOusv-ynquhQ~5e39be2261dcaf30274b0ef2efab00ce

Analysts' recommendations: Repligen Corporation

07-07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
05-15	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
04-17	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
02-25	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
01-16	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
01/10/25	HSBC Initiates Repligen at Buy With $150 Price Target	MT
22/09/25	Repligen Shares Rise After Upgrade From Evercore ISI	MT
22/09/25	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
03/09/25	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
30/07/25	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
29/07/25	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
01/07/25	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
24/06/25	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
30/04/25	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
29/04/25	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
08/04/25	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
18/03/25	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
21/02/25	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
21/02/25	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT
10/02/25	TD Cowen Initiates Repligen at Buy With $200 Price Target	MT
04/02/25	RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating	MT
09/12/24	RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating	MT
14/11/24	Wolfe Research Initiates Repligen at Peer Perform	MT
13/11/24	UBS Adjusts Price Target on Repligen to $190 From $185, Keeps Buy Rating	MT
13/09/24	RBC Raises Price Target on Repligen to $205 From $190, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REPLIGEN CORPORATION					+26.62%
	ABBOTT LABORATORIES					+21.45%
	MEDTRONIC PLC					+16.58%
	CENCORA, INC.					+16.1%
	HOYA CORPORATION					+18.46%
	BECTON, DICKINSON AND COMPANY					+13.19%
	MEDLINE INC.					+18.92%
	DEXCOM, INC.					+15.86%
	WEST PHARMACEUTICAL SERVICES, INC.					+1.96%
	TERUMO CORPORATION					+27.43%
	Average					+17.66%
	Weighted average by Cap.					+17.94%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

139.83USD

Average target price

177.05USD

Spread / Average Target

+26.62%

High Price Target

220.00USD

Spread / Highest target

+57.33%

Low Price Target

142.00USD

Spread / Lowest Target

+1.55%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Benchmark Company
Rothschild & Co Redburn
UBS
HSBC
Evercore ISI
RBC Capital Markets
Barclays
Wolfe Research
Deutsche Bank Securities
TD Cowen
Guggenheim
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright